Ifetroban is a potent and selective thromboxane receptor antagonist, and has been studied in other diseases. This drug is aimed at cardiac function and has shown to be effective in other cardiac indications. The current study aims to address the unmet medical need to treat Duchenne cardiomyopathy using a new therapeutic strategy for patients with Duchenne muscular dystrophy.

Status

A Phase 2 study is ongoing.

Sponsor

This program is sponsored by Cumberland Pharmaceuticals.

Related Studies

For information regarding current or upcoming clinical trials please visit our Explore Clinical Trials Page.

Media Library